Altrinsic Global Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Altrinsic Global Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-70,000	Closed	-$10.7M	–	84
2021 Q1	$10.7M	Hold	70,000	–	–	0.34%	45
2020 Q4	$10.9M	Hold	70,000	–	–	0.37%	42
2020 Q3	$8.01M	Hold	70,000	–	–	0.33%	42
2020 Q2	$7.86M	Sell	70,000 -5,000	-7%	-$531K	0.34%	39
2020 Q1	$6.73M	Buy	75,000 +10,000	+15%	+$981K	0.37%	40
2019 Q4	$7.03M	Hold	65,000	–	–	0.3%	40
2019 Q3	$6.37M	Hold	65,000	–	–	0.28%	43
2019 Q2	$8.51M	Hold	65,000	–	–	0.39%	41
2019 Q1	$8.79M	Hold	65,000	–	–	0.41%	42
2018 Q4	$6.33M	Buy	65,000 +5,000	+8%	+$591K	0.3%	44
2018 Q3	$8.34M	Buy	60,000 +10,000	+20%	+$1.25M	0.38%	41
2018 Q2	$6.21M	Hold	50,000	–	–	0.25%	44
2018 Q1	$5.57M	Buy	50,000 +5,000	+11%	+$598K	0.23%	43
2017 Q4	$5.38M	Buy	45,000 +20,000	+80%	+$2.44M	0.21%	46
2017 Q3	$3.51M	Sell	25,000 -5,000	-17%	-$679K	0.13%	59
2017 Q2	$3.65M	Buy	+30,000	New	+$3.49M	0.13%	62

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Altrinsic Global Advisors's ALXN Position: Q2 2021 in Review

Altrinsic Global Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 70,000 shares — an estimated $10.7M sold.

Altrinsic Global Advisors first reported a position in ALXN in Q2 2017 and held it in 16 quarters. The position peaked at $10.9M in Q4 2020. 710 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

Altrinsic Global Advisors reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Altrinsic Global Advisors sold 70,000 Alexion Pharmaceuticals shares in Q2 2021, an estimated $10.7M.
Altrinsic Global Advisors first reported a position in Alexion Pharmaceuticals in Q2 2017 and held it in 16 quarters.
Altrinsic Global Advisors's Alexion Pharmaceuticals position peaked at $10.9M in Q4 2020.
710 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Altrinsic Global Advisors's 13F filing for Q2 2021, filed 13 Aug 2021.